TY - JOUR AU - Jemal, A. AU - Siegel, R. AU - Ward, E. AU - Murray, T. AU - Xu, J. AU - Thun, M. J. PY - 2007 DA - 2007// TI - Cancer statistics JO - CA Cancer J Clin VL - 57 UR - https://doi.org/10.3322/canjclin.57.1.43 DO - 10.3322/canjclin.57.1.43 ID - Jemal2007 ER - TY - JOUR AU - Ang, K. K. AU - Harris, J. AU - Wheeler, R. AU - Weber, R. AU - Rosenthal, D. I. AU - Nguyen-Tan, P. F. AU - Westra, W. H. AU - Chung, C. H. AU - Jordan, R. C. AU - Lu, C. AU - Kim, H. AU - Axelrod, R. AU - Silverman, C. C. AU - Redmond, K. P. AU - Gillison, M. L. PY - 2010 DA - 2010// TI - Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer JO - N Engl J Med VL - 363 UR - https://doi.org/10.1056/NEJMoa0912217 DO - 10.1056/NEJMoa0912217 ID - Ang2010 ER - TY - JOUR AU - Folprecht, G. AU - Lutz, M. P. AU - Schoffski, P. AU - Seufferlein, T. AU - Nolting, A. PY - 2006 DA - 2006// TI - Pollert PCetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma JO - Ann Oncol VL - 17 UR - https://doi.org/10.1093/annonc/mdj084 DO - 10.1093/annonc/mdj084 ID - Folprecht2006 ER - TY - JOUR AU - Salomon, D. S. AU - Brandt, R. AU - Ciardiello, F. PY - 1995 DA - 1995// TI - Normanno NEpidermal growth factor-related peptides and their receptors in human malignancies JO - Crit Rev Oncol Hematol VL - 19 UR - https://doi.org/10.1016/1040-8428(94)00144-I DO - 10.1016/1040-8428(94)00144-I ID - Salomon1995 ER - TY - JOUR AU - Wilke, H. AU - Glynne-Jones, R. AU - Thaler, J. M. A. B. E. L. PY - 2006 DA - 2006// TI - A large multinational study of cetuximab plus irinotecan in irinotecan resistant metastatic colorectal cancer JO - J Clin Oncol VL - 24 ID - Wilke2006 ER - TY - JOUR AU - Ang, K. K. AU - Berkey, B. A. AU - Tu, X. AU - Zhang, H. Z. AU - Katz, R. AU - Hammond, E. H. AU - Fu, K. K. AU - Milas, L. PY - 2002 DA - 2002// TI - Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma JO - Cancer Res VL - 62 ID - Ang2002 ER - TY - JOUR AU - Licitra, E. AU - Felip, E. PY - 2009 DA - 2009// TI - Squamous cell carcinoma of the head and neck: ESMO Clinical Recommendations for diagnosis, treatment and follow-up JO - Ann Oncol VL - 20 ID - Licitra2009 ER - TY - JOUR AU - Grégoire, V. AU - Lefebvre, J. L. AU - Licitra, L. AU - Felip, E. PY - 2010 DA - 2010// TI - Squamous cell carcinoma of the head and neck: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up JO - Ann Oncol VL - 21 UR - https://doi.org/10.1093/annonc/mdq185 DO - 10.1093/annonc/mdq185 ID - Grégoire2010 ER - TY - JOUR AU - Bernier, J. AU - Schneider, D. PY - 2007 DA - 2007// TI - Cetuximab combined with radiotherapy: an alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck? JO - Eur J Cancer VL - 43 UR - https://doi.org/10.1016/j.ejca.2006.08.035 DO - 10.1016/j.ejca.2006.08.035 ID - Bernier2007 ER - TY - JOUR AU - Rowan, K. PY - 2010 DA - 2010// TI - Should Cetuximab replace cisplatin in head and neck cancer? JO - J Natl Cancer Inst VL - 102 UR - https://doi.org/10.1093/jnci/djp531 DO - 10.1093/jnci/djp531 ID - Rowan2010 ER - TY - JOUR AU - Bonner, J. A. AU - Harari, P. M. AU - Giralt, J. AU - Cohen, R. B. AU - Jones, C. U. AU - Sur, R. K. PY - 2010 DA - 2010// TI - Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival JO - Lancet Oncol VL - 11 UR - https://doi.org/10.1016/S1470-2045(09)70311-0 DO - 10.1016/S1470-2045(09)70311-0 ID - Bonner2010 ER - TY - JOUR AU - Bonner, J. A. AU - Harari, P. M. AU - Giralt, J. AU - Azarnia, N. AU - Shin, D. M. AU - Cohen, R. B. AU - Jones, C. U. AU - Sur, R. AU - Raben, D. AU - Jassem, J. AU - Ove, R. AU - Kies, M. S. AU - Baselga, J. AU - Youssoutian, H. AU - Amellal, N. AU - Rowinsky, E. K. AU - Ang, K. K. PY - 2006 DA - 2006// TI - Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck JO - N Engl J Med VL - 354 UR - https://doi.org/10.1056/NEJMoa053422 DO - 10.1056/NEJMoa053422 ID - Bonner2006 ER - TY - JOUR AU - Baselga, J. PY - 2001 DA - 2001// TI - The EGFR as a target for anticancer therapy--focus on cetuximab JO - Eur J Cancer VL - 37 UR - https://doi.org/10.1016/S0959-8049(01)00233-7 DO - 10.1016/S0959-8049(01)00233-7 ID - Baselga2001 ER - TY - JOUR AU - Fan, Z. AU - Baselga, J. AU - Masui, H. PY - 1993 DA - 1993// TI - Mendelsohn JAntitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts JO - Cancer Res VL - 53 ID - Fan1993 ER - TY - JOUR AU - Milas, L. AU - Mason, K. AU - Hunter, N. AU - Petersen, S. AU - Yamakawa, M. PY - 2000 DA - 2000// TI - Ang KIn vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody JO - Clin Cancer Res VL - 6 ID - Milas2000 ER - TY - JOUR AU - Caudell, J. J. AU - Sawrie, S. M. AU - Spencer, S. A. AU - Desmoid, R. A. AU - Carroll, W. R. AU - Peters, G. E. PY - 2008 DA - 2008// TI - Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment JO - Int J Radiat Oncol Biol Phys VL - 71 UR - https://doi.org/10.1016/j.ijrobp.2007.10.040 DO - 10.1016/j.ijrobp.2007.10.040 ID - Caudell2008 ER - TY - JOUR AU - Li, T. AU - Perez-Soler, R. PY - 2009 DA - 2009// TI - Skin toxicities associated with epidermal growth factor receptor inhibitors JO - Target Oncol VL - 4 UR - https://doi.org/10.1007/s11523-009-0114-0 DO - 10.1007/s11523-009-0114-0 ID - Li2009 ER - TY - JOUR AU - Segaert, S. AU - Van Cutsem, E. PY - 2005 DA - 2005// TI - Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors JO - Ann Oncol VL - 16 UR - https://doi.org/10.1093/annonc/mdi279 DO - 10.1093/annonc/mdi279 ID - Segaert2005 ER - TY - JOUR AU - Segaert, S. PY - 2008 DA - 2008// TI - Management of skin toxicity of epidermal growth factor receptor inhibitors JO - Target Oncol VL - 3 UR - https://doi.org/10.1007/s11523-008-0092-7 DO - 10.1007/s11523-008-0092-7 ID - Segaert2008 ER - TY - JOUR AU - Perez-Soler, R. PY - 2009 DA - 2009// TI - Skin toxicities associated with epidermal growth factor receptor inhibitors JO - Target Oncol VL - 4 UR - https://doi.org/10.1007/s11523-009-0114-0 DO - 10.1007/s11523-009-0114-0 ID - Perez-Soler2009 ER - TY - JOUR AU - Potthoff, K. AU - Hofheinz, R. AU - Hassel, J. C. AU - Volkenandt, M. AU - Lordick, F. AU - Hartmann, J. T. AU - Karthaus, M. AU - Riess, H. AU - Lipp, H. P. AU - Hauschild, A. AU - Trarbach, T. AU - Wollenberg, A. PY - 2011 DA - 2011// TI - Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion JO - Ann Oncol VL - 22 UR - https://doi.org/10.1093/annonc/mdq387 DO - 10.1093/annonc/mdq387 ID - Potthoff2011 ER - TY - STD TI - Garcia-Huttenlocher HI, Timke C, Dinkel J, Huber PE, Debus J, Muenter MW: Acute Toxicity of Skin and Mucosa in Patients with Head and Neck Cancer Receiving Radiotherapy Alone or in Combination with Chemotherapy or Cetuximab. Proceedings of the 5th Annual ASTRO Meeting. Budach W, Bölke E, Homey B ID - ref22 ER - TY - JOUR AU - Budach, W. AU - Bölke, E. AU - Homey, B. PY - 2007 DA - 2007// TI - Severe cutaneous reaction during radiation therapy with concurrent cetuximab JO - N Engl J Med VL - 357 UR - https://doi.org/10.1056/NEJMc071075 DO - 10.1056/NEJMc071075 ID - Budach2007 ER - TY - JOUR AU - Mitchell, E. P. AU - Perez-Soler, R. AU - Van Cutsem, E. AU - Lacouture, M. E. PY - 2007 DA - 2007// TI - Clinical presentation and pathophysiology of EGFRI dermatologic toxicities JO - Oncology (Williston Park) VL - 11 ID - Mitchell2007 ER - TY - JOUR AU - Saltz, L. B. AU - Meropol, N. J. AU - Loehrer, P. J. AU - Needle, M. N. AU - Kopit, J. AU - Mayer, R. J. PY - 2004 DA - 2004// TI - Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor JO - J ClinOncol VL - 1 UR - https://doi.org/10.1200/JCO.2004.10.182 DO - 10.1200/JCO.2004.10.182 ID - Saltz2004 ER - TY - JOUR AU - Peeters, M. AU - Siena, S. AU - Van Cutsem, E. PY - 2009 DA - 2009// TI - Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy JO - Cancer VL - 115 UR - https://doi.org/10.1002/cncr.24088 DO - 10.1002/cncr.24088 ID - Peeters2009 ER - TY - JOUR AU - Vermorken, J. B. AU - Trigo, J. AU - Hitt, R. PY - 2007 DA - 2007// TI - Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2006.06.7447 DO - 10.1200/JCO.2006.06.7447 ID - Vermorken2007 ER - TY - JOUR AU - Bonner, J. A. AU - Ang, K. PY - 2007 DA - 2007// TI - More on severe cutaneous reaction with radiotherapy and cetuximab JO - N Engl J Med VL - 357 UR - https://doi.org/10.1056/NEJMc076359 DO - 10.1056/NEJMc076359 ID - Bonner2007 ER - TY - JOUR AU - Giro, C. AU - Berger, B. AU - Bölke, E. AU - Ciernuk, I. F. AU - Duprez, F. AU - Locati, L. AU - Maillard, S. AU - Ozsahin, M. AU - Pfeffer, R. AU - Robertson, G. AU - Langendijk, J. A. PY - 2009 DA - 2009// TI - Budach WHigh rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: Results of a survey in EORTC institutes JO - Radiother Oncol VL - 90 UR - https://doi.org/10.1016/j.radonc.2008.09.007 DO - 10.1016/j.radonc.2008.09.007 ID - Giro2009 ER - TY - BOOK PY - 2012 DA - 2012// TI - Summary of product characteristics ID - ref30 ER - TY - JOUR AU - Kumar, B. AU - Cordell, K. G. AU - Lee, J. S. AU - Worden, F. P. AU - Prince, M. E. AU - Tran, H. H. AU - Wolf, G. T. AU - Urba, S. G. AU - Chepeha, D. B. AU - Teknos, T. N. AU - Eisbruch, A. AU - Tsien, C. I. AU - Taylor, J. M. AU - D’Silva, N. J. AU - Yang, K. AU - Kurnit, D. M. AU - Bauer, J. A. AU - Bradford, C. R. AU - Carey, T. E. PY - 2008 DA - 2008// TI - EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.12.7662 DO - 10.1200/JCO.2007.12.7662 ID - Kumar2008 ER - TY - JOUR AU - Lassen, P. AU - Eriksen, J. G. AU - Hamilton-Dutoit, S. AU - Tramm, T. AU - Alsner, J. AU - Overgaard, J. PY - 2009 DA - 2009// TI - Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.20.2853 DO - 10.1200/JCO.2008.20.2853 ID - Lassen2009 ER - TY - JOUR AU - Ang, K. K. AU - Harris, J. AU - Wheeler, R. AU - Weber, R. AU - Rosenthal, D. I. AU - Nguyen-Tan, P. F. AU - Westra, W. H. AU - Chung, C. H. AU - Jordan, R. C. AU - Lu, C. AU - Kim, H. AU - Axelrod, R. AU - Silverman, C. C. AU - Redmond, K. P. AU - Gillison, M. L. PY - 2010 DA - 2010// TI - Human papillomavirus and survival of patients with oropharyngeal cancer JO - N Engl J Med VL - 363 UR - https://doi.org/10.1056/NEJMoa0912217 DO - 10.1056/NEJMoa0912217 ID - Ang2010 ER - TY - STD TI - Common Terminology Criteria for Adverse Events v4.02 (CTCAE). 2012, http://evs.nci.nih.gov/ftp1/CTCAE/Archive/CTCAE_4.02_2009-09-15_QuickReference_5x7_Locked.pdf, UR - http://evs.nci.nih.gov/ftp1/CTCAE/Archive/CTCAE_4.02_2009-09-15_QuickReference_5x7_Locked.pdf ID - ref34 ER - TY - STD TI - Common Terminology Criteria for Adverse Events v3.0 (CTCAE). 2012, http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf, UR - http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf ID - ref35 ER - TY - JOUR AU - Eisenhauer, E. A. AU - Therasse, P. AU - Bogaerts, J. AU - Schwartzd, L. H. AU - Sargente, D. AU - Fordf, R. AU - Danceyg, J. AU - Arbuckh, S. AU - Gwytheri, S. AU - Mooneyg, M. AU - Rubinsteing, L. AU - Shankarg, L. AU - Doddg, L. AU - Kaplanj, R. AU - Lacombec, D. AU - Verweij, J. PY - 2009 DA - 2009// TI - New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) JO - Eur J Cancer VL - 45 UR - https://doi.org/10.1016/j.ejca.2008.10.026 DO - 10.1016/j.ejca.2008.10.026 ID - Eisenhauer2009 ER - TY - STD TI - NCCN guidelines for physicians. 2012, http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf, UR - http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf ID - ref37 ER - TY - JOUR AU - Marur, S. PY - 2010 DA - 2010// TI - HPV-associated head and neck cancer: a virus-related cancer epidemic JO - Lancet Oncol VL - 11 UR - https://doi.org/10.1016/S1470-2045(10)70017-6 DO - 10.1016/S1470-2045(10)70017-6 ID - Marur2010 ER - TY - JOUR AU - Erber, R. AU - Conradt, C. AU - Homann, N. AU - Enders, C. AU - Finckh, M. AU - Dietz, A. AU - Weidauer, H. AU - Bosch, F. X. PY - 1998 DA - 1998// TI - TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer JO - Oncogene VL - 16 UR - https://doi.org/10.1038/sj.onc.1201690 DO - 10.1038/sj.onc.1201690 ID - Erber1998 ER - TY - JOUR AU - Cabelguenne, A. AU - Blons, H. AU - De Waziers, I. AU - Carnot, F. AU - Houllier, A. M. AU - Soussi, T. AU - Brasnu, D. AU - Beaune, P. AU - Laccourreye, O. AU - Laurent-Puig, P. PY - 2000 DA - 2000// TI - p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series JO - J Clin Oncol VL - 18 ID - Cabelguenne2000 ER - TY - JOUR AU - Temam, S. AU - Flahault, A. AU - Perie, S. AU - Monceaux, G. AU - Coulet, F. AU - Callard, P. AU - Bernaudin, J. F. AU - St Guily, J. L. AU - Fouret, P. PY - 2000 DA - 2000// TI - p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck JO - J Clin Oncol VL - 18 ID - Temam2000 ER - TY - JOUR AU - Poeta, M. L. AU - Manola, J. AU - Goldwasser, M. A. AU - Forastiere, A. AU - Benoit, N. AU - Califano, J. A. AU - Ridge, J. A. AU - Goodwin, J. AU - Kenady, D. AU - Saunders, J. AU - Westra, W. AU - Sidransky, D. AU - Koch, W. M. PY - 2007 DA - 2007// TI - TP53 mutations and survival in squamous-cell carcinoma of the head and neck JO - N Engl J Med VL - 357 UR - https://doi.org/10.1056/NEJMoa073770 DO - 10.1056/NEJMoa073770 ID - Poeta2007 ER - TY - JOUR AU - Forastiere, A. AU - Koch, W. AU - Trotti, A. PY - 2001 DA - 2001// TI - Head and neck cancer JO - N Engl J Med VL - 345 UR - https://doi.org/10.1056/NEJMra001375 DO - 10.1056/NEJMra001375 ID - Forastiere2001 ER - TY - JOUR AU - Saltz, L. AU - Kies, M. AU - Abbruzeese, J. L. PY - 2003 DA - 2003// TI - Presence and intensity of the cetuximab-induced acne-rash predicts increased survival in studies across multiple malignancies JO - Proc Am Soc Clin Oncol VL - 22 UR - https://doi.org/10.1200/JCO.2004.99.242 DO - 10.1200/JCO.2004.99.242 ID - Saltz2003 ER - TY - JOUR AU - Wong, S. F. AU - Lloyd, K. AU - Vasko, C. PY - 2007 DA - 2007// TI - A pilot cross-over study to evaluate the use of Regenecare topical gel in patients with cutaneous toxicity caused by epidermal growth factor receptor (HER1/EGFR) inhibitors JO - Oncol Nurs Forum VL - 34 ID - Wong2007 ER - TY - JOUR AU - Wacker, B. AU - Nagrani, T. AU - Weinberg, J. PY - 2007 DA - 2007// TI - Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies JO - Clin Cancer Res VL - 13 UR - https://doi.org/10.1158/1078-0432.CCR-06-2610 DO - 10.1158/1078-0432.CCR-06-2610 ID - Wacker2007 ER - TY - JOUR AU - Perez-Soler, R. AU - Saltz, L. PY - 2005 DA - 2005// TI - Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.00.6916 DO - 10.1200/JCO.2005.00.6916 ID - Perez-Soler2005 ER - TY - JOUR AU - Racca, P. AU - Fanchini, L. AU - Caliendo, V. AU - Ritorto, G. AU - Evangelista, W. AU - Volpatto, R. AU - Milanesi, E. AU - Ciorba, A. AU - Paris, M. AU - Facilissimo, I. AU - Macripò, G. AU - Clerico, M. AU - Ciuffreda, L. PY - 2008 DA - 2008// TI - Efficacy and skin toxicity management with cetuximab in metastaticcolorectal cancer: outcomes from an oncologic/dermatologic cooperation JO - Clin Colorectal Cancer VL - 7 UR - https://doi.org/10.3816/CCC.2008.n.007 DO - 10.3816/CCC.2008.n.007 ID - Racca2008 ER - TY - STD TI - The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/13/345/prepub UR - http://www.biomedcentral.com/1471-2407/13/345/prepub ID - ref49 ER -